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ABSTRACT 
The efficacy of low dose systemic opioids for chronic breathlessness was questioned by the  
recent Cochrane review by Barnes 2016. We examined the reasons for this conflicting finding 
and re-evaluated the efficacy of systemic opioids. 
Compared with previous meta-analyses, Barnes 2016 reported a smaller effect and lower 
precision, but did not account for matched data of crossover trials (11/12 included trials) and 
added a risk-of-bias criterion (sample size). When re-analyzed to account for crossover data, 
opioids decreased breathlessness (SMD −0.32; −0.18 to −0.47; I2=44.8%) representing a 
clinically meaningful reduction of 0.8 points (0−10 numerical rating scale), consistent across 
meta-analyses.  
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INTRODUCTION 
Chronic breathlessness [1] is common across a range of advanced diseases and associated 
with major adverse health outcomes.[2] The candidate treatment with best evidence to date is 
regular, low-dose, non-nebulized (systemic) morphine.[2] The efficacy of low dose systemic 
opioids was supported by a Cochrane review of Jennings 2001,[3 4] an adequately powered 
crossover-trial in 2003,[5] and the meta-analysis in people with severe chronic obstructive 
pulmonary disease (COPD) by Ekström 2015.[6]  
A new Cochrane meta-analysis by Barnes 2016,[7] drawing from a similar evidence base, 
reported a smaller benefit of opioids than the other reviews, and wider 95% confidence 
intervals (CI) which nearly crossed zero. The risk of bias was rated as ‘high’ for all studies; 
previous ratings were mainly ‘unclear’ or ‘low’.[3 4 6] Barnes 2016 rated the quality of 
evidence for opioids for breathlessness as ‘very low’.[7]  
We aimed to determine the reasons for the different conclusions and to re-evaluate the 
efficacy of systemic opioids for chronic breathlessness. 
 
METHODS 
Data were extracted from the published meta-analyses by Jennings 2001,[3 4] Ekström 
2015,[6] and Barnes 2016 [7] (by ME), and cross-validated (DCC and MJJ) regarding study 
populations, designs, interventions, and methods, for the whole study population and in 
participants with COPD, respectively.  
Breathlessness measures were analyzed as standardized mean differences (SMD).[8] For 
cross-over trials, the standard error was estimated using the cross-over information, directly 
from the published report or calculated from significance test statistics as recommended.[8] 
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The effect of opioids compared with placebo was analyzed using a random effects model. A 
detailed description of the statistical methods is given in the online supplement (Appendix 1). 
 
RESULTS 
Included studies 
All included studies were double-blind, placebo-controlled randomized trials; 13/14 studies 
were crossover designs (Table 1). Jennings 2001 and Barnes 2016 included patients with any 
advanced, life-limiting disease, whereas Ekström 2015 restricted the analysis to patients with 
COPD. Research questions, interventions, comparisons and treatment durations were similar 
between the three meta-analyses (Table 1). 
The study populations overlapped significantly with over half of the studies in Barnes 2016 
also included in Jennings 2001 and Ekström 2015 (Table S1 in the online supplement). For 
two studies omitted by Barnes 2016, the reasons for exclusion were not stated.  
 
Efficacy 
In contrast to the other meta-analyses, Barnes 2016 used a fixed effects model which does not 
account for variations in the true effect between studies, and analyzed all data as if from 
parallel trials and did not account for matched crossover data (11/12; 92% of included 
studies). 
Opioids were associated with a decrease in breathlessness in both Jennings 2001 and Ekström 
2015 (Table 1). In the primary analysis of Ekström 2015, systemic opioids improved 
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breathlessness in COPD outpatients measured at steady state (five studies, 91 participants), 
SMD −0.33 (95% CI, −0.52 to −0.14). 
Barnes 2016 split the analysis by route of administration and type of outcome measure (Table 
1). Point estimates of efficacy ranged from SMD −0.27 (oral opioid, post treatment scores) to 
mean difference 0.20 (subcutaneous opioid, change scores). Precision was markedly lower 
across all analyses. The estimate for COPD in Barnes 2016 included all types of both 
systemic and nebulized opioids. Estimates for systemic opioids or efficacy at steady state 
were not reported. 
When Barnes 2016 was re-analyzed using a random effects model accounting for crossover 
data (Figure 1), opioids decreased breathlessness, SMD −0.32 (95% CI, −0.47 to −0.18; P < 
0.001; I2 = 44.8%) compared with placebo, consistent with Jennings 2001 and Ekström 2015. 
Using the standard deviation from a large study,[5] this effect size corresponds to a reduction 
of 0.8 points on a 0-10 numerical rating scale (NRS). The finding was consistent when 
excluding the three studies for which the standard errors were imputed.  
 
Risk of bias and quality of evidence 
Conclusions regarding risk of bias were similar between Jennings 2001 and Ekström 2015 
with unclear or low risk of bias for most items (Table 1). In contrast, Barnes 2016 categorized 
all studies as having high risk of bias due to low sample size defined as < 50 participants in 
each treatment arm. This criterion had no stated rationale and resulted in the quality of 
evidence for systemic opioids being downgraded from moderate (Ekström 2015) to low or 
very low in Barnes 2016 (Table 1). 
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DISCUSSION 
The conflicting findings regarding the efficacy of opioids for chronic breathlessness in the 
recent Cochrane review are likely due to their use of inappropriate methodology. When re-
analyzed to account for crossover data, opioids were associated with a statistically and 
clinically significant reduction in breathlessness,[9] consistent across meta-analyses.[3 4 6]  
Analyzing crossover studies as parallel studies can result in selection bias, with spuriously too 
high or too low effect estimates, as well as reduced precision.[10] Recommended methods to 
account for crossover data are available [10] and were used by Jennings 2001 and Ekström 
2015.[3 4 6]  In addition, study selection should align to pre-defined eligibility criteria with 
reasons for exclusion stated to minimize selection bias.  
While any judgement of risk of bias is subjective, the bias criterion related to study size 
introduced by Barnes 2016, which resulted in all studies being rates as high risk of bias, is 
questionable. It is the power of the study which could lead to bias, and not the sample size per 
se which is based on the power calculation. Adequate power can be provided by trials with 
total sample sizes below 50,[5] especially in crossover trials where the participant acts as their 
own control thus increasing power. 
We suggest that the analysis by Barnes 2016 and the relevant guidelines for analysis and 
review of the Cochrane Collaboration are updated to accommodate these issues.  
 
CONCLUSION 
Moderate level evidence to date supports that regular, low dose morphine is the first line 
pharmacological treatment for the relief of chronic breathlessness in severe illness. 
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TABLES 
Table 1. Characteristics of meta-analyses of systemic opioids for breathlessness 
Characteristic of meta-
analysis 
Jennings 2001[3] Ekström 2015[6] Barnes 2016[7] 
Design of included 
studies (n) 
Double-blind RCTs Double-blind RCTs Double-blind RCTs 
N studies 9 (all crossover trials) 8 (all crossover trials) 12 (1 parallel and 11 crossover trials) 
N trial participants 102 118 198 
Population (n trial 
participants) 
COPD (n=80); chronic heart 
failure (n=12); cancer (n=10); 
COPD (n=113); other (n=5) COPD (n=107); CHF (n=47); Cancer (n=41); 
other (n=3) 
Intervention Oral or parenteral opioid Oral or parenteral opioid Oral or parenteral opioid 
Comparison Placebo Placebo Placebo or any other pharmacological or non-
pharmacological interventions that were directly 
compared with the opioid treatment (only 2 trials 
used non-placebo comparator) 
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Duration of treatment (n 
studies) 
Single or few doses (N=5); 
longer treatment of one to six 
weeks (n=4) 
Single dose  or one day 
(n=3); four days to six weeks 
(n=5)  
Single dose or 1-2 days (n=7); four days to six 
weeks (n=5) 
Statistical method for 
pooling 
Random effect models.  
Change on different scales 
compared as SMDs   
Random effect models.  
Change on different scales 
compared as SMDs  
 Fixed effect models. 
Changes compared as MD when on the same 
scale and SMD when on separate scales, and 
separately for change from baseline and post 
scores. 
Random effect model was used in a sensitivity 
analysis. 
Accounted for cross-over 
designs 
Yes Yes No (analyzed data as from parallel trials) 
Findings for whole study 
population 
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Pooled effect of 
opioids (95% CI; I2; n 
trial participants)* 
SMD -0.40 (−0.63 to −0.17; 
I2=42.3% ; n=102) 
SMD −0.34 (−0.58 to −0.10; 
I2=0%; n=118) 
Oral opioid, change from baseline: SMD 0.07 
(−0.30 to 0.44; I2= 65%; n=116)  
Oral opioid, post scores: SMD −0.27 (−0.56 to 
0.02; I2= 0%; n=190) 
Sc. opioid, change from baseline: MD 0.20 (−2.50 
to 2.90; n=20) 
Stated quality of 
evidence 
Not stated Moderate (GRADE) Not stated for systemic opioids 
For opioids overall:  very low for change from 
baseline and low for post scores (GRADE)** 
Findings in COPD 
participants 
   
Pooled effect of 
opioids (95% CI; I2; n 
trial participants)* 
SMD −0.26 (−0.44 to 0.08; 
I2=23.6%; n=80)** 
SMD −0.34 (−0.58 to −0.10; 
I2=0%; n=118) 
Change from baseline: SMD −0.49 (−1.08 to 0.10; 
I2= 0%; n=46)**  
Post scores: SMD −0.21 (−0.45 to 0.04; I2= 0%; 
n=262)** 
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Stated quality of 
evidence (criteria) 
Not stated Moderate (GRADE) Not stated 
Risk of bias assessment Using Jadad score of methods 
of randomization and blinded. 
Most items were rated as 
unclear  
Using the Cochrane risk of 
bias tool. Ratings were low 
or unclear for all items; no 
item was rated as high 
Using the Cochrane risk of bias tool as well as an 
additional item based on study size: ≥ 200 (low 
risk), 50−199 (unclear risk) and < 50 (high risk) 
participants in each treatment arm. 
 
All items in the Cochrane risk of bias tool were 
rated as low or unclear except three items rated as 
high: performance bias (n=1), detection bias 
(n=1) and other bias (n=1).**  
 
Risk of study size bias was rated as high risk for 
all studies. 
Characteristics are for trials included in each published meta-analysis.[3 6 7]  
* Negative estimate indicates reduction in breathlessness by opioids compared with placebo. 
** Included both trials of systemic and nebulized opioids which were not reported separately. 
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Abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; GRADE = Grading of Recommendations Assessment, Development, and 
Evaluation; I2 = proportion of the total variance in effect estimates that are between studies; MD = mean difference; RCT = randomized controlled trial; Sc = subcutaneous; 
SMD = standardized mean difference. 
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FIGURE LEGENDS 
 
Figure 1.  The meta-analysis of Barnes et al.[7] re-analyzed using random effects model and 
accounting for matched data of cross-over trials. In the pooled analysis compared to placebo, 
systemic opioids reduced breathlessness by a mean 0.32 (95% CI, 0.18 to 0.47; P < 0.001) 
standard deviations. 
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Appendix 1. Statistical analyses 
 
The included trials were mostly (13 of 14) cross-over designs, but also included one parallel 
group study. The trials used a variety of measures of breathlessness including the Borg scale 
and visual analogue scales. To combine differences estimated on different scales, we 
standardized by dividing estimated treatment differences and their standard error by the 
standard deviation of the breathlessness index between participants. [1 2]  We followed the 
recommendation of Curtin et al.[24] that “when combining standardized results from cross-
over trials with those of parallel trials, the cross-over estimator sb corresponds to s of parallel 
trials and only this standardization should be used.” For cross-over trials, the standard 
deviation between participants was estimated by averaging the variances under the treatment 
conditions, or from a pre-treatment observation.  For cross-over trials, the standard error was 
estimated using the cross-over information. This was done directly from the published report 
or calculated from significance test statistics or P values. For three studies,[3-5] all that was 
available was an upper limit for the P values, e.g. P<0.05. This upper limit was used to 
calculate the standard error, making the standard error slightly too large and the analysis 
slightly conservative. In three cases,[6-8] it was not possible find a standard error from the 
publication. As these all used the Borg scale, the variance of within-participant differences 
was found from the other cross-over studies which reported this scale and the average 
variance was used to impute the standard error for the studies where this was unavailable. As 
a sensitivity analysis, the meta-analysis was done including and excluding these studies. All 
estimates were expressed with 95% confidence intervals and, as the trials varied in treatment 
and medical condition of participants, a random effects estimate was used. This meant that 
any extra within-study variability produced by the standardization was automatically included 
in the error and did not need to be estimated explicitly. 
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Of the studies included by Barnes et al 2016, the study of Bar-Or et al.[9] was excluded as 
data suitable for the analysis were not found in the publication. The meta-analysis was also 
repeated including the study of Johnson et al [10] that was excluded in Barnes 2016 for 
reasons which were unclear, using the original raw data, with similar findings. Meta-analyses 
were using the software Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ). 
Data were entered as standardized differences and their standardized standard errors. Pooled 
estimates were obtained using a random effects model by the method of DerSimonian and 
Laird. The study and pooled estimates were presented as a forest plot drawn using Stata 
version 13 (StataCorp LP, College Station, TX). 
 
  
4 
 
Table S1. Included trials of and reasons for exclusion in meta-analyses of systemic 
opioids for chronic breathlessness 
Trial 
Jennings 2001 [11]
n=9 
Ekström 2015 [12]
n=8 
Barnes 2016 [13] 
n=12 
Abernethy 2003 Not published yet Yes Yes 
Bar-Or 1982 Letter only Letter only Yes 
Bruera 1993 Yes Not COPD Yes 
Chua 1997 Yes Not COPD Yes 
Eiser 1991a Yes Yes Yes 
Eiser 1991b Yes Yes Not stated 
Hui 2014 Not published yet Not COPD Yes 
Johnson 1983 Yes Yes Yes 
Light 1996 Yes Yes Yes 
Mazzocato 1999 Not published yet* Not COPD Yes 
Oxberry 2011 Not published yet Not COPD Yes 
Poole 1998 Yes Yes Yes 
Woodcock 1981 Yes Yes Yes 
Woodcock 1982 Yes Yes Not stated 
Included studies and stated reasons for exclusion for trials in the published meta-analyses. 
* Jennings 2001 performed the last search in May 1999. 
Abbreviations: CHF = chronic heart failure; 
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